

# About Pfizer's Centers for Therapeutic Innovation (CTI)



# CTI Basics

## CTI Vision

Accelerate the translation of innovative discoveries from bench to clinic

## About CTI

- Founded in 2010, CTI is an entrepreneurial group that partners with academic medical centers and foundations to translate promising science into clinical candidates.
- CTI's work is based on authentic collaboration, reflected in shared decision making and aligned incentives.
- We are an entrepreneurial, results-driven group committed to transforming the R&D ecosystem, bringing together some of the world's best resources – including patients, academic researchers, foundations, and our own scientists – to develop medicines faster and more efficiently.

## Our Approach

- Entrepreneurial
- Collaborative
- Results-driven

# CTI's Approach to Partnerships

- What this is
  - **Translational, getting new therapeutics to the clinic quickly**
  - Fair and transparent
  - Focused research plans based on agreed-upon deliverables
  - Clear set of go/no-go criteria
  - Success-based rewards
- What this is not
  - Target identification/validation or exploratory research
  - Open-ended “grant-like” funding
  - Unilateral effort



# CTI's Academic Network

25 Leading Academic Medical Centers, 70 External Academic Reviewers,  
8 National Academy of Science Members



CTI -  
Boston



Children's Hospital Boston



Harvard University



Beth Israel Deaconess Medical Center



CTI -  
New York



MOUNT SINAI  
SCHOOL OF  
MEDICINE



NEW YORK UNIVERSITY



The Children's Hospital  
of Philadelphia®



HOSPITAL FOR  
SPECIAL SURGERY



COLUMBIA  
UNIVERSITY



CTI -  
California



University of California  
San Francisco

Sanford|Burnham  
Medical Research Institute

Stanford University



BENAROYA  
RESEARCH INSTITUTE  
UNLOCKING THE IMMUNE SYSTEM

# CTI's Network of Small-molecule Partners

## 10 Academic Medical Centers



Beth Israel Deaconess  
Medical Center



Children's Hospital Boston



NEW YORK UNIVERSITY

## Small-molecule Targets

Kinases

Solute  
Transporters

Serine Hydrolase

Epigenetic Targets

# CTI's Call for Proposals Process



- Principal investigators are invited to submit a 2-3 page non-confidential pre-proposal. The pre-proposal outlines scientific background and provides a synopsis of the research plan.
- The Joint Steering Committee, comprised equally of CTI/Pfizer members and AMC-appointed experts, reviews pre-proposals and agrees upon pre-proposals to advance.



- PIs whose projects are chosen are invited to submit an 8-10 page full proposal co-authored by a CTI scientist. These proposals contain confidential information, including a detailed research plan, drug candidate characteristics, and a brief outline of the Phase 1 study for clinical translation.
- The JSC reviews proposals, then meets to discuss and agree upon proposals to matriculate into CTI's pipeline.



- Chosen PIs, in collaboration with CTI's scientists, create a Statement of Work outlining their research plan, timeline and budget.
- Projects must meet agreed-upon milestones to maintain their position in CTI's pipeline.

# CTI's Pre-Proposal Guidelines



# What CTI Looks For

- **Strong Project Rationale**
  - Demonstrated association between target biology, pathway and disease mechanism
  - Target validation as demonstrated by genetic or pharmacologic evidence
- **Therapeutic Area Opportunity**
  - Unmet medical needs, opportunity for novel therapeutic mechanism or modality
- **Therapeutic Drug Target**
  - Novel target, novel therapeutic strategy or new insight into target patient population
  - Defined target
  - Demonstrated cause/effect relationship to disease mechanism
  - Understanding of desired pharmacology
  - Tractability of target relative to drug modalities (monoclonal antibodies, peptides, proteins or small molecules), available reagents, assays and technologies
- **Project Feasibility**
  - Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, preclinical testing, etc.)
  - Clear path to FIH clinical trial (approach for proof-of-mechanism in humans, accessible patient population, timeframe, safety issues, etc.)
- **Ability to Translate Basic Biological Research into the Clinic**
  - From molecular mechanism to therapeutic opportunity
  - Personalized medicine, patient stratification, molecular signatures, genetic associations, biomarkers

# What CTI Does Not Look For

- Target Discovery
  - Technologies or projects looking for new target
- Exploratory Research
  - Development of animal models, cell line models, indication expansion or mechanism of action for existing drugs
- Platform Technology
  - Vaccine platform, RNAi platform, screening platform
- Pre-clinical or Clinical Drug Candidates
  - IND-ready candidates or clinical trials candidates
  - Note: *CTI may consider proposals for pre-existing drug candidates based upon discussions with PI and Technology Transfer Office*
- In-licensing Opportunities